Par Health recalls two lots of Brevital Sodium injection over cellulose particles

Par Health announced a voluntary recall of two lots of its Brevital® Sodium 500 mg/vial for injection after detecting particulate matter identified as cellulose.

The recall is being executed at the hospital level, and the company reports no adverse events associated with the affected lots.

The presence of cellulose particles could potentially cause serious health consequences, including pulmonary emboli, vascular occlusions, or vein inflammation.

Par Health urges healthcare providers to remove the recalled product from inventory and follow standard return procedures.